FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:2830-2832 June 29, 2006 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Antman, E. M. PubMed Citation

To the Editor: On behalf of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment (ExTRACT)–Thrombolysis in Myocardial Infarction (TIMI) 25 Study investigators, Antman et al. (April 6 issue)¹ compared the use of seven days of enoxaparin with 48 hours of unfractionated heparin in patients receiving fibrinolysis for ST-elevation myocardial infarction. The longer duration of treatment with enoxaparin was found to be superior to the short course of treatment with unfractionated heparin, although the longer treatment was associated with an increase in major bleeding episodes. One may conclude from this study that enoxaparin provides superior anticoagulation to that of . . . [Full Text of this Article]

This article has been cited by other articles:

• Bassand, J.-P. (2008). The place of fondaparinux in the ESC and ACC/AHA guidelines for anticoagulation in patients with non-ST elevation acute coronary syndromes. Eur Heart J Suppl 10: C22-C29 [Abstract] [Full Text]  
• De Caterina, R., Husted, S., Wallentin, L., Agnelli, G., Bachmann, F., Baigent, C., Jespersen, J., Kristensen, S. D., Montalescot, G., Siegbahn, A., Verheugt, F. W.A., Weitz, J. (2007). Anticoagulants in heart disease: current status and perspectives. Eur Heart J 0: ehl492v1-34 [Full Text]